Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01497327 · ClinicalTrials.gov registry record · Phase 1

Open-Label Hepatic Impairment Study

A Phase 1 study of Hepatitis C, sponsored by Gilead Sciences.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
2
Study locations

NCT01497327: Completed Phase 1 study of Hepatitis C, sponsored by Gilead Sciences.

NCT01497327 is a Phase 1 study of Hepatitis C that has completed, run by Gilead Sciences. The registered enrollment target is 24 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01497327, a Phase 1 study of Hepatitis C, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

This study will be conducted in Hepatitis C positive patients to determine whether the pharmacodynamic effects of PSI-7977 or PSI-352938 are similar to HCV-infected patients with normal hepatic function, which may allow inclusion of patients with cirrhosis and varying degrees of hepatic dysfunction in future clinical studies.

Primary Outcome

To characterize the pharmacokinetics (PK) of PSI-352938 over 7 days of dosing with PSI-352938 in HCV-infected patients with varying degrees of hepatic impairment compared to historical PK data.

Conditions Studied

Interventions

  • DRUG PSI-352938
  • DRUG PSI-7977

Study Locations (2)

Texas

  • - San Antonio

Puerto Rico

  • - San Juan

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2011-07
Est. Completion 2012-01
Phase Phase 1
Gilead Sciences

504 total trials

What the finished NCT01497327 record still lists

NCT01497327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which PSI-352938 is the first listed.

NCT01497327 reports a single indexed study location in Texas, Puerto Rico.

Frequently Asked Questions

What is clinical trial NCT01497327 about?

NCT01497327 is a clinical study titled "Open-Label Hepatic Impairment Study". This study will be conducted in Hepatitis C positive patients to determine whether the pharmacodynamic effects of PSI-7977 or PSI-352938 are similar to HCV-infected patients with normal hepatic function, which may allow inclusion of patients with cirrhosis and varying degrees of hepatic dysfunction ...

What is the current status of trial NCT01497327?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-07. Estimated completion is 2012-01.

What conditions does trial NCT01497327 study?

This clinical trial studies the following conditions: Hepatitis C.

What interventions are being tested in trial NCT01497327?

The interventions under investigation include: PSI-352938 (DRUG), PSI-7977 (DRUG).

Who is sponsoring clinical trial NCT01497327?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01497327 being conducted?

This trial has 2 study locations across Texas, Puerto Rico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01497327's enrollment target sits among peer trials

24 91st of 106 higher than 16 of 106 other Hepatitis C trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01497327, the US trial registry maintained by the National Library of Medicine. NCT01497327 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.